Sartorius Stedim Biotech
This fully integrated technology platform (photo) combines an expression system with equipment and process control for the rapid development and scaleup of robust, high-titer commercial manufacturing processes. By leveraging this upstream technology platform, biopharmaceutical manufacturers will be able to reach the clinic in 14 months, says the company. The system accelerates clone selection and scales up readily to Biostat STR single-use bioreactors, which biomanufacturers have successfully implemented at pilot and GMP production scales. — Sartorius Stedim Biotech, Göttingen, Germany